{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:48:37Z","timestamp":1793191717662,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceuticals Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T04:21:19Z","timestamp":1710994879000},"page":"14-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation"],"prefix":"10.1016","volume":"237","author":[{"given":"Yuto","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.thromres.2024.03.021_bb0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.thromres.2024.03.021_bb0010","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia a","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.021_bb0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.021_bb0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.021_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102271","article-title":"NXT007-mediated hemostatic potential is suppressed by activated protein C catalyzed inactivation of activated factor V","volume":"8","author":"Nakajima","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.021_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/SLA.0b013e3181bdf8ad","article-title":"Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism","volume":"251","author":"Kawanaka","year":"2010","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.021_bb0035","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1055\/s-0038-1636538","article-title":"Emicizumab, a bispecific antibody to factors IX\/IXa and X\/Xa, does not interfere with antithrombin or TFPI activity in vitro","volume":"2","author":"Noguchi-Sasaki","year":"2018","journal-title":"TH. Open."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.021_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/01.ATV.17.2.409","article-title":"The effect of immunodepletion of antithrombin III on the response of rabbits to Russell\u2019s viper venom-induced activation of factor X","volume":"17","author":"Rapaport","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10386","key":"10.1016\/j.thromres.2024.03.021_bb0045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.021_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:52:10Z","timestamp":1758736330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"alternative-id":["S0049384824001026"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}